Illumina, Inc. (ILMN)
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips
ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.
Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates
Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago.
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance
Illumina eyes Q4 growth on NovaSeq X momentum, new multiomic launches and stronger sequencing demand despite China export limits.
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Illumina's New Connected Multiomics Platform Set to Boost Its Stock
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
